« Return to News | Awards & Advancement

Peter Alterman named COO of SAFE-BioPharma

Monday, August 13, 2012 03:13 PM

Peter Alterman, Ph.D., who held numerous senior information security positions within the U.S. federal government, has been named chief operating officer of SAFE-BioPharma Association, the strategic, non-profit collaboration responsible for the global SAFE-BioPharma digital identity and digital signature standard used in the life science and healthcare sectors.
 
Alterman recently retired after 33 years of government service where, most recently, he was senior advisor to the national program office of the National Strategy for Trusted Identities in Cyberspace (NSTIC), NIST. Before that he served as senior advisor to the NIH CIO for Strategic Initiatives, Assistant CIO for e-authentication at the National Institutes of Health and chair of the U.S. Federal PKI Policy Authority. His role in Internet technology started in 1989 as a member of the Federal Research Internet Coordinating Committee.
  
In addition to responsibilities for a variety of association management functions, Alterman will serve as SAFE-BioPharma’s primary liaison with the FDA and other global regulatory authorities and represent the association’s interests on global standards and policy bodies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.